ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response

ADCC-Inducing Antibody Trastuzumab and Selection of KIR-HLA Ligand Mismatched Donors Enhance the NK Cell Anti-Breast Cancer Response

Natural killer (NK)-cell-based immunotherapies are an attractive treatment option for cancer. We previously showed that alloreactive mouse NK cells cured mice of 4T1 breast cancer. However, the tumor microenvironment can inhibit immune responses, and these suppressive factors must be overcome to unf...

Full description

Bibliographic Details
Main Authors: Femke A. I. Ehlers, Nicky A. Beelen, Michel van Gelder, Tom M. J. Evers, Marjolein L. Smidt, Loes F. S. Kooreman, Gerard M. J. Bos, Lotte Wieten
Format: Article
Language:English
Published: MDPI AG 2021-06-01
Series:Cancers
Subjects:
alloreactive donor NK cells
HLA class I
antibody-dependent cellular cytotoxicity
breast cancer
tumor microenvironment
Online Access:https://www.mdpi.com/2072-6694/13/13/3232

Internet

https://www.mdpi.com/2072-6694/13/13/3232

Similar Items